FdaApplication
NDA 213082
Identifiers
- fda_app_no: NDA213082
Properties
| Property | Value |
|---|---|
| applicant_name | PFIZER INC |
| application_type | NDA |
| approval_date | 2020-09-25 |
Revenue by product
XELJANZ
| Period | Revenue |
|---|---|
| Q2 2026 | $251.0M |
| Q1 2026 | $180.0M |
| Q3 2025 | $313.0M |
| Q2 2025 | $322.0M |
| Q1 2025 | $128.0M |
| Q3 2024 | $321.0M |
| Q2 2024 | $303.0M |
| Q1 2024 | $194.0M |
| Q4 2023 | $493.0M |
| Q3 2023 | $503.0M |
| Q2 2023 | $469.0M |
| Q1 2023 | $237.0M |
| Q4 2022 | $492.0M |
| Q3 2022 | $502.0M |
| Q2 2022 | $430.0M |
| Q1 2022 | $372.0M |
| Q4 2021 | $721.0M |
| Q3 2021 | $610.0M |
| Q2 2021 | $586.0M |
| Q1 2021 | $538.0M |
| Q4 2020 | $696.0M |
| Q3 2020 | $654.0M |
| Q2 2020 | $635.0M |
| Q1 2020 | $451.0M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (1)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| XELJANZ | TOFACITINIB CITRATE | EQ 1MG BASE/ML | SOLUTION;ORAL |
1 product